# Analgecine for the Treatment of Neuropathic Pain

> **NCT02633618** · PHASE3 · COMPLETED · sponsor: **VanWorld Pharmaceutical (Rugao) Company Limited** · enrollment: 135 (actual)

## Conditions studied

- Neuropathic Pain

## Interventions

- **BIOLOGICAL:** Analgecine
- **BIOLOGICAL:** Neurotropin

## Key facts

- **NCT ID:** NCT02633618
- **Lead sponsor:** VanWorld Pharmaceutical (Rugao) Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2015-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02633618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02633618, "Analgecine for the Treatment of Neuropathic Pain". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02633618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*